CA-TIGO
9.7.2024 15:01:30 CEST | Business Wire | Press release
Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy software solutions, today unveiled a new set of powerful and customizable features of the Tigo Energy Intelligence (EI) Platform. With a newly retooled, upgraded, and tiered approach to delivering the right solar monitoring and insights, even small and mid-sized installation companies can manage their growing solar customer portfolios sustainably. These platform enhancements come online as the U.S. installed base of solar surpasses the 5 million solar installations threshold and the industry considers how it will manage the O&M work as those numbers double by 2030 and triple by 2034.
The Tigo EI Platform now offers upgrade options that deliver even more of the right information at the right time via a user-friendly interface to installers, asset managers, and down to the individual system owner. Most notably for rapidly scaling installers, EPCs, and O&M providers, the new EI Professional package provides a centralized view of critical health and performance data of all systems under management. Beyond a scalable monitoring experience and a simple, flat-price model, the EI Professional package includes:
- one-click enrollment for company-wide, unlimited-seat subscription access covering all systems under management,
- a portfolio-wide dashboard with a prioritized view into critical data, such as health status, production, performance, equipment status, location data, and commissioning time tracking, and
- time-saving features including advanced tagging, grouping, and site filtering for improved management, maintenance, optimization, and trend analysis.
Solar installers use the Tigo EI Platform to gain improved insights into installation status, decrease O&M costs, and monitor energy generation and system performance. The standard system-by-system monitoring view, now named EI Basic, remains free of charge, and includes module-level resolution and insight into third-party hardware. More advanced monitoring and analytics tools, historical data, and minute-level monitoring resolution, among others, are available via a simple, in-platform upgrade to EI Premium.
“As we watch the number, size, and complexity of the residential and commercial systems we deploy increase, we found that the only way to scale was with a comprehensive way to monitor, diagnose, and optimize those systems,” said Garrett Brandt, owner at Radius Energy. “When you consider the cost of even a single truck roll or the opportunity cost of a one-week delay in getting an invoice out post-commissioning, a paid subscription to avoid either makes sense right away. The features now available via the Tigo EI Platform don’t just add value in terms of savings but represent new opportunities for us on the installer side.”
Installer training materials for the EI Platform are now available in the Tigo Academy. Tigo Academy offers new and existing customers and installers an efficient way to learn about Tigo software through hands-on demonstrations and tutorials on how to leverage Tigo software for optimal system performance and customer satisfaction.
“To stay competitive, installers have to become more agile while providing more post-installation services, which is why Tigo has developed increasingly sophisticated options in the EI Platform that deliver the right management tools to the variety of customers we serve,” said Archie Roboostoff, vice president of software, at Tigo Energy. “Software plays an increasingly important role in ensuring that solar deployments reach peak performance while continuously analyzing trends to see where improvements can be made. The EI Platform is designed to identify system issues before production is impacted. System owners expect quality and reliability, and the EI Platform helps to deliver both.”
To learn more about the Tigo EI Platform, including the standard capabilities of EI Basic and the features and subscription pricing for EI Premium and EI Professional, please visit the EI features page at https://www.tigoenergy.com/ei/pricing. Tigo installers are also invited to take advantage of promotional trial access to EI Professional for the month of July, which is available via web browser on the Tigo EI Platform: https://ei.tigoenergy.com/
About Tigo Energy
Founded in 2007, Tigo is a worldwide leader in the development and manufacture of smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Tigo combines its Flex MLPE (Module Level Power Electronics) and solar optimizer technology with intelligent, cloud-based software capabilities for advanced energy monitoring and control. Tigo MLPE products maximize performance, enable real-time energy monitoring, and provide code-required rapid shutdown at the module level. The company also develops and manufactures products such as inverters and battery storage systems for the residential solar-plus-storage market. For more information, please visit www.tigoenergy.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709862359/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
